pharma · Atherosclerosis · Non-small Cell Lung Cancer (NSCLC)
MSD Merck Sharp
Merck Sharp and Dohme
Merck Sharp and is a pharma organization headquartered in EU. Primary therapeutic focus areas include Atherosclerosis, Non-small Cell Lung Cancer (NSCLC), Hypercholesterolemia, HIV infection, Acute and chronic Pain. Nova
WERFTESTRASSE 4, Lucerne, 6005, ch HQ
61 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- WERFTESTRASSE 4, Lucerne, 6005, ch
- Employees
- 61
- Programs
- 217
- Drugs
- 180
- Patents
- 0
MK-2870-019
Phase 3 · small molecule · Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2])
MK-2870-019 for Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2]) is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Internal code MK-2870-019
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Merck Sharp and Dohme
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB (with nodal involvement [N2])
- Status
- active
- Trials
- 1